Multiple Sclerosis is an unpredictable, often devastating disease of the central nervous system that disrupts the flow of information between the brain and the body. The cause of MS is currently unknown. MS can be separated into two subtypes: relapsing & remitting MS and progressive MS.
Our team has independently engineered a pro-drug with proprietary chemical structure that targets an underlying mechanism of progressive MS with secondary benefits to relapsing and remitting MS. As a result, our medication may prevent both relapses and progression in MS, and thereby significantly improve the quality of life for MS patients.
The Science Behind Medicine
Cutting Edge Methodologies
Diagnosed MS Cases Are Relapsing & Remitting
Diagnosed MS Cases Are Considered Progressive
Million People Diagnosed With Multiple Sclerosis
Thousand People Died From Multiple Sclerosis in 2013
Industry Leading Innovation
Reduce Disease and Improve Health
Glixis aims to reduce the progression of disease, streamline treatment process, and improve a patient’s quality of life one pill at a time.
World Renowned Leaders
Leaders who want to fundamentally revolutionize the treatment options & potential therapies for multiple sclerosis patients.
First Of Its Kind Compound
Glixis has developed a first-of-its-kind compound that treats the underlying pathophysiology of multiple sclerosis.
Causes of Multiple Sclerosis
Symptoms of MS
- vision problems
- tingling and numbness
- vertigo and dizziness
- muscle weakness and spasms
- problems with balance and coordination
Other, less common, symptoms include:
- speech and swallowing problems
- cognitive dysfunction
- difficulty with walking
- bladder and bowel dysfunction
- sexual dysfunction
- mood swings, depression
Cost of Care
Women and MS
Other Commerical Medications
- teriflunomide (Aubagio)
- interferon beta-1a (Avonex, Rebif, Plegridy)
- interferon beta-1b (Betaseron, Extavia)
- glatiramer acetate (Copaxone)
- fingolimod (Gilenya)
- mitoxantrone (Novantrone)
- dimethyl fumarate (Tecfidera)
- natalizumab (Tysabri)
- alemtuzumab (Lemtrada)
Research Based ApproachOur novel compound targets the underlying genetic and molecular defect in MS pathogenesis by correcting a key metabolic pathway in protein N-glycosylation. Pioneering research by our group has shown in both mice and humans that a defect in protein N-glycosylation promotes inflammatory demyelination and neurodegeneration.